Remove 2022 Remove Pharmaceutical Companies Remove Vaccines
article thumbnail

Pharmaceutical microbiology: key developments 2022

European Pharmaceutical Review

This Q&A covers the key developments in pharmaceutical microbiology in 2022, featuring insight from pharmaceutical microbiology experts: Dr Tim Sandle, Head of Microbiology, Bio Products Laboratory Limited. Regulation, particularly Annex 1, was identified as a key focus for 2022.

Vaccines 128
article thumbnail

Cancer vaccines: providing the edge in oncology

pharmaphorum

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. The oncology segment has been recognised as one of the most productive areas for pharmaceutical companies to focus their R&D investment.

Vaccines 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Meet the 2022 FOYA Social Impact Category Winner: Janssen Biologics

ISPE

Meet the 2022 FOYA Social Impact Category Winner: Janssen Biologics. Wed, 09/21/2022 - 11:34. Meet the 2022 FOYA Social Impact Category Winner: Janssen Biologics. 21 September 2022. Catalent is the other winner of the Social Impact FOYA for 2022. Vaccines are a major part of this effort. Trudy Patterson.

article thumbnail

2022 ISPE Annual Meeting: Transform, Collaborate, & Innovate for the Path Forward

ISPE

2022 ISPE Annual Meeting: Transform, Collaborate, & Innovate for the Path Forward. Wed, 11/02/2022 - 07:32. 2022 ISPE Annual Meeting: Transform, Collaborate, & Innovate for the Path Forward. 2 November 2022. Pfizer “cleared runway to allow for large-scale vaccine manufacturing before we had a product!” iSpeak Blog.

article thumbnail

Market cap growth surges for over half of the top biopharmaceutical companies in 2022

Pharmaceutical Technology

The 13 top players experienced significant growth over 2022 despite the decline in demand for COVID-19 vaccines and therapeutics, as well as uncertainty surrounding pricing due to the newly passed Inflation Reduction Act in the US. billion on Dec 31, 2022. Merck & Co. Merck & Co. billion to $281.3 to $365.84.

article thumbnail

The Pandemic Treaty and the opportunity to end ‘vaccine apartheid’

pharmaphorum

Ben Hargreaves discovers why some have referred to the distribution of COVID-19 vaccines and treatments as a form of apartheid. Vaccine access for a price. Tendayi Achium, labelled the response by the global community as a form of “vaccine apartheid,” a suggestion echoed by the organisation’s director general.

article thumbnail

Big Pharma leading in access-to-medicine strategies, shows data

European Pharmaceutical Review

To ensure people in LMICs have access to new and innovative medicines and vaccines as soon as possible after launch, companies need to have an access plan in place for products in the pipeline from at least Phase II of R&D. The research showed 83 percent of pharmaceutical companies are putting more strategies in place.